FY2026 EPS Estimates for Roche Cut by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Analysts at Erste Group Bank cut their FY2026 earnings per share (EPS) estimates for shares of Roche in a research note issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $3.14 for the year, down from their previous forecast of $3.16. The consensus estimate for Roche’s current full-year earnings is $3.06 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.41 EPS.

A number of other brokerages also recently issued reports on RHHBY. HSBC restated a “hold” rating on shares of Roche in a research report on Thursday. Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price on the stock in a research note on Friday, August 7th. Royal Bank Of Canada assumed coverage on shares of Roche in a report on Tuesday, September 8th. They issued an “outperform” rating for the company. Finally, Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Roche Stock Performance

Shares of Roche stock opened at $54.80 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. The stock has a 50 day moving average price of $54.49 and a 200-day moving average price of $52.53. Roche has a one year low of $39.50 and a one year high of $60.85.

Hedge Funds Weigh In On Roche

Several hedge funds have recently bought and sold shares of the business. McIlrath & Eck LLC purchased a new position in Roche in the 1st quarter worth about $39,000. Renasant Bank bought a new position in Roche in the 2nd quarter worth about $210,000. Pinnacle Wealth Management Advisory Group LLC bought a new position in Roche in the 1st quarter worth about $208,000. Sarver Vrooman Wealth Advisors purchased a new position in shares of Roche during the fourth quarter worth approximately $287,000. Finally, Enterprise Financial Services Corp raised its stake in shares of Roche by 6.6% during the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after acquiring an additional 345 shares in the last quarter.

About Roche

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.